The proteasomal inhibitor MG132 prevents muscular dystrophy in zebrafish.
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Using sapje zebrafish which lack dystrophin, we have assessed both the quantitation of muscle damage in dystrophic fish, and the efficacy of the proteasomal inhibitor MG132 in reducing the dystrophic symptoms. Fourier analysis of birefringence patterns in normal and dystrophic fish was found to be a simple and reliable quantitative measure of muscle damage. MG132, as in mdx mouse, was found to be effective in reducing muscle damage with an EC50 of 0.4µM. This study adds further to the utility of zebrafish as a model of choice for testing muscular dystrophy therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“MG-132 also improves the dystrophic phenotype in a model of dystrophin deficiency (Bonuccelli et al., 2003; Winder et al., 2011).”
From Proteasome dysfunction induces muscle growth defects and protein aggregation (2014) · cites this paper as Winder et al., 2011
The cited source says what the claim attributes to it.
In the citing paper
“MG-132 also improved the dystrophic phenotype in a model of dystrophin deficiency (Bonuccelli et al., 2003; Winder et al., 2011).”
From Proteasome dysfunction induces muscle growth defects and protein aggregation (2014) · cites this paper as Winder et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Random Data-Analysis and Measurement Procedures
Bendat, J. S., Piersol, A. G., & Saunders, H. (1989) · Journal of Vibration and Acoustics · doi:10.1115/1.3269865 · Cited by 6,375
Zebrafish: from disease modeling to drug discovery.
Rubinstein, A. L. (2003) · PubMed · Cited by 292
Zebrafish: A Complete Animal Model for In Vivo Drug Discovery and Development
Chakraborty, C., Hsu, C., Wen, Z., Lin, C., & Agoramoorthy, G. (2009) · Current Drug Metabolism · doi:10.2174/138920009787522197 · Cited by 279 · cited 1×
“The zebrafish Danio rerio , has rapidly been adopted as an organism of choice for all aspects of the drug discovery pipeline [ [1] , [2] , [3] ].”
Dystrophin is required for the formation of stable muscle attachments in the zebrafish embryo
Bassett, D. I., Bryson-Richardson, R. J., Daggett, D. F., Gautier, P., Keenan, D. G., & Currie, P. D. (2003) · Development · doi:10.1242/dev.00799 · Cited by 270
Drug screening in a zebrafish model of Duchenne muscular dystrophy
Kawahara, G., Karpf, J. A., Myers, J. A., Alexander, M. S., Guyon, J. R., & Kunkel, L. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102116108 · Cited by 191 · cited 2×
“A recent screen from the Kunkel Group has also validated this approach and identified a number of compounds that appear effective in reducing dystrophic symptoms in zebrafish [9] , in particular PDE5 inhibitors appear to be useful in this regard as they have also been shown to be effective in mdx mice [ [10] , [11] ].”
Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy
Adamo, C. M., Dai, D.-F., Percival, J. M., Minami, E., Willis, M. S., Patrucco, E., Froehner, S. C., & Beavo, J. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013077107 · Cited by 162 · cited 1×
“A recent screen from the Kunkel Group has also validated this approach and identified a number of compounds that appear effective in reducing dystrophic symptoms in zebrafish [9] , in particular PDE5 inhibitors appear to be useful in this regard as they have also been shown to be effective in mdx mice [ [10] , [11] ].”
The zebrafish as a model for muscular dystrophy and congenital myopathy
Bassett, D. I., & Currie, P. D. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg279 · Cited by 156 · cited 2×
“The zebrafish system offers unique advantage for drug screening in a vertebrate model organism, and in particular muscular dystrophies are especially amenable due to their early, robust and readily recognisable phenotypes [ [4] , [5] ].”
James, M., Nuttall, A., Ilsley, J. L., Ottersbach, K., Tinsley, J. M., Sudol, M., & Winder, S. J. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.10.1717 · Cited by 149
Self-citationModeling human muscle disease in zebrafish
Guyon, J. R., Steffen, L. S., Howell, M. H., Pusack, T. J., Lawrence, C., & Kunkel, L. M. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.07.003 · Cited by 149 · cited 2×
“The zebrafish system offers unique advantage for drug screening in a vertebrate model organism, and in particular muscular dystrophies are especially amenable due to their early, robust and readily recognisable phenotypes [ [4] , [5] ].”
Asai, A., Sahani, N., Kaneki, M., Ouchi, Y., Martyn, J. A. J., & Yasuhara, S. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000806 · Cited by 140 · cited 1×
“A recent screen from the Kunkel Group has also validated this approach and identified a number of compounds that appear effective in reducing dystrophic symptoms in zebrafish [9] , in particular PDE5 inhibitors appear to be useful in this regard as they have also been shown to be effective in mdx mice [ [10] , [11] ].”
Research works printed but not linked: 1
- Harris FJ (1978) On the use of the windows for harmonic analysis with the discrete Fourier transform. Proc IEEE 66: 51-84.
Cited by
Hübner, K., Cabochette, P., Diéguez-Hurtado, R., Wiesner, C., Wakayama, Y., Grassme, K. S., Hubert, M., Guenther, S., Belting, H.-G., Affolter, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07302-x · Cited by 84
Proteasome dysfunction induces muscle growth defects and protein aggregation
Kitajima, Y., Tashiro, Y., Suzuki, N., Warita, H., Kato, M., Tateyama, M., Ando, R., Izumi, R., Yamazaki, M., Abe, M., et al. (2014) · Journal of Cell Science · doi:10.1242/jcs.150961 · Cited by 79
“MG-132 also improves the dystrophic phenotype in a model of dystrophin deficiency (Bonuccelli et al., 2003; Winder et al., 2011).”
BackgroundMG132-mediated inhibition of the ubiquitin–proteasome pathway ameliorates cancer cachexia
Zhang, L., Tang, H., Kou, Y., Li, R., Zheng, Y., Wang, Q., Zhou, X., & Jin, L. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1412-6 · Cited by 72
“Our results are consistent with previous studies which showed that MG132 prevented muscle dystrophy (Winder et al.”
ResultFluoxetine prevents dystrophic changes in a zebrafish model of Duchenne muscular dystrophy
Waugh, T. A., Horstick, E. J., Hur, J., Jackson, S. W., Davidson, A. E., Li, X., & Dowling, J. J. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu185 · Cited by 74
Pirolli, D., Sciandra, F., Bozzi, M., Giardina, B., Brancaccio, A., & Rosa, M. C. D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103866 · Cited by 67
Metadata
- Authors
- Winder, S. J., Lipscomb, L., Angela Parkin, C., & Juusola, M.
- Affiliations
- University of Sheffield (GB)
- ORCID
- Juusola, Mikko
- Venue
- PLoS Currents
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-11-17
- Volume
- 3
- Pages
- RRN1286
- ISSN
- 2157-3999 (ISSN-L)
- PMC
- PMC3219425
- OpenAlex
- W2109714653
- Cited by
- 30
- References
- 20
- Citations by year
- 2024: 4 · 2023: 1 · 2021: 2 · 2020: 2 · 2018: 3 · 2017: 1 · 2016: 2 · 2015: 4 · 2014: 5 · 2013: 3 · 2012: 3
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by
- Locations
- PLoS Currents (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Zebrafish Biomedical Research Applications
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- muscular dystrophy, MG132, proteasome inhibitors, dystrophin, muscle damage, birefringence, Fourier analysis, zebrafish model, treatment efficacy, mdx mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


